27/47
2.9 / 5 stars
All 47 Win/Lose results and 73 gray no-data contests shown below
BBIO Roast Me summary
BridgeBio Pharma, Inc. (BBIO). Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth No data.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth No data.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth No data.
Trailing 1 year (4 quarters): 7 wins, 1 losses, 4 no dataLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/2 |
LoseBBIO / S&P 0.30% / 15.20% |
WinBBIO / S&P 202.39% / 15.00% |
No dataBBIO / S&P / 50.40% |
| 2026-Q12/2 |
WinBBIO / S&P -2.92% / -4.33% |
WinBBIO / S&P 355.17% / 11.30% |
No dataBBIO / S&P / 27.70% |
| 2025-Q42/2 |
WinBBIO / S&P 47.27% / 2.65% |
WinBBIO / S&P 126.26% / 9.00% |
No dataBBIO / S&P / 13.40% |
| 2025-Q32/2 |
WinBBIO / S&P 20.29% / 8.12% |
WinBBIO / S&P 62.46% / 4.61% |
No dataBBIO / S&P / 13.45% |
| 2025-Q22/2 |
WinBBIO / S&P 24.91% / 10.94% |
WinBBIO / S&P 7.62% / 4.83% |
No dataBBIO / S&P / 10.63% |
| 2025-Q11/2 |
WinBBIO / S&P 25.98% / -4.27% |
LoseBBIO / S&P -41.71% / 4.98% |
No dataBBIO / S&P / 10.57% |
| 2024-Q42/2 |
WinBBIO / S&P 7.78% / 2.41% |
WinBBIO / S&P 2285.27% / 5.25% |
No dataBBIO / S&P / 6.15% |
| 2024-Q31/2 |
LoseBBIO / S&P 0.51% / 5.89% |
WinBBIO / S&P 2209.77% / 5.89% |
No dataBBIO / S&P / 6.11% |
| 2024-Q21/2 |
LoseBBIO / S&P -18.08% / 4.28% |
WinBBIO / S&P 3761.22% / 5.38% |
No dataBBIO / S&P / 5.12% |
| 2024-Q11/2 |
LoseBBIO / S&P -23.41% / 10.56% |
WinBBIO / S&P 181.05% / 5.71% |
No dataBBIO / S&P / 5.59% |
| 2023-Q41/2 |
WinBBIO / S&P 53.09% / 11.69% |
LoseBBIO / S&P -88.02% / 6.81% |
No dataBBIO / S&P / 7.78% |
| 2023-Q31/2 |
WinBBIO / S&P 53.31% / -3.27% |
LoseBBIO / S&P -89.37% / 7.52% |
No dataBBIO / S&P / -5.03% |
| 2023-Q20/2 |
LoseBBIO / S&P 3.74% / 8.74% |
LoseBBIO / S&P -93.74% / 9.50% |
No dataBBIO / S&P / -8.57% |
| 2023-Q11/2 |
WinBBIO / S&P 117.59% / 7.50% |
LoseBBIO / S&P 9.63% / 10.77% |
No dataBBIO / S&P / -15.69% |
| 2022-Q40/2 |
LoseBBIO / S&P -23.34% / 7.56% |
LoseBBIO / S&P 11.38% / 11.88% |
No dataBBIO / S&P / -17.99% |
| 2022-Q32/2 |
WinBBIO / S&P 9.47% / -4.88% |
WinBBIO / S&P 55.68% / 13.47% |
No dataBBIO / S&P / -1.41% |
| 2022-Q22/2 |
WinBBIO / S&P -10.54% / -16.10% |
WinBBIO / S&P 44.53% / 13.71% |
No dataBBIO / S&P / 11.04% |
| 2022-Q10/1 |
LoseBBIO / S&P -39.15% / -4.60% |
No dataBBIO / S&P / 15.97% |
No dataBBIO / S&P / 42.23% |
| 2021-Q41/2 |
LoseBBIO / S&P -64.41% / 11.03% |
WinBBIO / S&P 745.14% / 15.00% |
No dataBBIO / S&P / 96.40% |
| 2021-Q30/1 |
LoseBBIO / S&P -23.11% / 0.58% |
No dataBBIO / S&P / 10.77% |
No dataBBIO / S&P / 69.42% |
| 2021-Q20/1 |
LoseBBIO / S&P -1.04% / 8.55% |
No dataBBIO / S&P / 6.58% |
No dataBBIO / S&P / 51.81% |
| 2021-Q10/1 |
LoseBBIO / S&P -13.37% / 6.17% |
No dataBBIO / S&P / -1.06% |
No dataBBIO / S&P / 7.39% |
| 2020-Q41/2 |
WinBBIO / S&P 89.53% / 12.15% |
LoseBBIO / S&P -79.66% / -3.72% |
No dataBBIO / S&P / -33.42% |
| 2020-Q31/1 |
WinBBIO / S&P 15.06% / 8.93% |
No dataBBIO / S&P / -2.04% |
No dataBBIO / S&P / -27.10% |
| 2020-Q20/1 |
LoseBBIO / S&P 12.45% / 20.54% |
No dataBBIO / S&P / -0.46% |
No dataBBIO / S&P / -27.11% |
| 2020-Q11/1 |
WinBBIO / S&P -17.26% / -19.60% |
No dataBBIO / S&P / 3.47% |
No dataBBIO / S&P / -14.75% |
| 2019-Q41/1 |
WinBBIO / S&P 63.25% / 9.07% |
No dataBBIO / S&P / 5.36% |
No dataBBIO / S&P / 2.99% |
| 2019-Q30/1 |
LoseBBIO / S&P -20.39% / 1.70% |
No dataBBIO / S&P / 5.02% |
No dataBBIO / S&P / 0.21% |
| 2019-Q20/0 |
No dataBBIO / S&P / 4.30% |
No dataBBIO / S&P / 6.64% |
No dataBBIO / S&P / 8.65% |
| 2019-Q10/0 |
No dataBBIO / S&P / 13.65% |
No dataBBIO / S&P / 8.12% |
No dataBBIO / S&P / 14.29% |
| 2018-Q40/0 |
No dataBBIO / S&P / -13.52% |
No dataBBIO / S&P / 9.05% |
No dataBBIO / S&P / 18.23% |
| 2018-Q30/0 |
No dataBBIO / S&P / 7.71% |
No dataBBIO / S&P / 10.21% |
No dataBBIO / S&P / 19.06% |
| 2018-Q20/0 |
No dataBBIO / S&P / 3.43% |
No dataBBIO / S&P / 9.03% |
No dataBBIO / S&P / 14.46% |
| 2018-Q10/0 |
No dataBBIO / S&P / -0.76% |
No dataBBIO / S&P / 7.68% |
No dataBBIO / S&P / 12.46% |
| 2017-Q40/0 |
No dataBBIO / S&P / 6.64% |
No dataBBIO / S&P / 7.03% |
No dataBBIO / S&P / 13.82% |
| 2017-Q30/0 |
No dataBBIO / S&P / 4.48% |
No dataBBIO / S&P / 5.68% |
No dataBBIO / S&P / 17.57% |
| 2017-Q20/0 |
No dataBBIO / S&P / 3.09% |
No dataBBIO / S&P / 4.83% |
No dataBBIO / S&P / 17.74% |
| 2017-Q10/0 |
No dataBBIO / S&P / 6.07% |
No dataBBIO / S&P / 3.67% |
No dataBBIO / S&P / 13.32% |
| 2016-Q40/0 |
No dataBBIO / S&P / 3.82% |
No dataBBIO / S&P / 2.09% |
No dataBBIO / S&P / 7.05% |
| 2016-Q30/0 |
No dataBBIO / S&P / 3.85% |
No dataBBIO / S&P / 0.20% |
No dataBBIO / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | BBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 48.03% | 20.78% |
| Annualized return | 48.03% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | BBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 51.30% | 83.14% |
| Annualized return | 8.63% | 12.86% |
10Y · 2019-06-27 to 2026-08-28
| Metric | BBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 178.11% | 319.30% |
| Annualized return | 10.77% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |